Hydroflumethiazide/Reserpine

氢氟噻嗪/利血平

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHydroflumethiazide/Reserpine
Drug Alias Name利血平/氢氟噻嗪Reserpine and HydroflumethiazideReserpine/HydroflumethiazideHydroflumethiazide and ReserpineSalutensin-demi +[6] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsSynaptic vesicular amine transporter inhibitors
TargetsThiazide-sensitive sodium-chloride cotransporterSynaptic vesicular amine transporter
Therapy Area/IndicationsEdemaHypertension
Global Approved IndicationsEdemaHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1960/06/20
Country/TerritoryUnited StatesMainland China
CombinationsYes ReserpineHydroflumethiazide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesBestway Pharmaceutical Co Ltd
Inactive CompaniesShire Development Llc
Active IndicationsHypertension
Inactive IndicationsEdema

Other Information

ATC CodeC02AA52C02LA01C03AH02
Related LinksN/A